The unprecedented health crisis that is particularly affecting Europe has highlighted our continent's shortcomings in terms of health sovereignty. As the cradle of pharmaceutical synthesis, Europe has gradually lost its capacity to develop new production processes.
SEQ
SEQENS
Company · France · EU Transparency Register 790576352506-25
2
positions filed
in the 665 files tracked
2
legislative files
of 665 tracked
1
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 665 consultation files tracked so far (57,774 submissions, mostly 2021–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 1210 companies & groups on this site, they rank #744 by legislative files engaged, a count of participation, not a measure of influence.
0.2
declared lobbying FTE
self-declared
€10K+
declared costs / yr (floor)
0
EP accreditations
as declared to the register
2024
in the register since
Declares membership of
- CEFIC (https://cefic.org/)
- France Chimie (https://www.francechimie.fr/)
- EFCG (https://efcg.cefic.org/)
- SICOS (https://chimiefine-biochimie.fr/Le-SICOS-Biochimie)
- UNIDEN (https://www.uniden.fr/)
- MEDEF (https://www.medef.com/fr/)
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026).
- Register category
- Companies & groups
- Head office
- Ecully, France
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track SEQENS in PolicySpeak: request access →
Work at SEQENS? so we know who speaks for it.
Their record over time
SEQENS filed 2 positions between 26 Apr 2021 and 1 Jun 2026, across 2 of the 665 legislative files tracked here, attaching a full position paper 1 time.
2021 · 1 filed2026 · 1 filed
What they argued
Seqens response EU ETS benchmark revision (20262030) Seqens welcomes the opportunity to provide input on the revision of EU ETS benchmark values for the 20262030 period. As an energy-intensive chemical company, Seqens supports the objectives of the EU ETS as a key instrument to drive decarbonization.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put SEQENS next to another organization. Same files, same register facts, side by side. Compare →
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers, not evidence of coordination, and we do not suggest any.
Is this your organization?
Everything on this page comes from SEQENS’s own submissions to the European Commission. We have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.